# A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML

> **NCT04038437** · PHASE1 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** CPX-351
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04038437
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-15
- **Primary completion:** 2022-04-26
- **Final completion:** 2022-09-24
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2022-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04038437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04038437, "A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04038437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*